Whereas the luminal BC subtype, ER+ HER2-negative, is typically responsive to endocrine therapy (ET), chemotherapy has an enhanced efficacy with both the HER2+ and basal-like TNBC [6,7,8]. Here, ERBB2 is linked to breast cancer.